Effects of breast size on breast reconstruction in BRCA mutation carriers and genetic high-risk patients after bilateral mastectomy.

Martin C Lam, Vendela Grufman, Sonia Fertsch, Florian Recker, Nicole E Speck, Jian Farhadi
Author Information
  1. Martin C Lam: Plastic Surgery Group, Zurich, Switzerland. martin.lam.research@gmail.com. ORCID
  2. Vendela Grufman: Plastic Surgery Group, Zurich, Switzerland.
  3. Sonia Fertsch: Plastic Surgery Group, Zurich, Switzerland.
  4. Florian Recker: Department of Gynecology and Obstetrics, University Hospital Bonn, University of Bonn, Bonn, Germany.
  5. Nicole E Speck: Plastic Surgery Group, Zurich, Switzerland.
  6. Jian Farhadi: Plastic Surgery Group, Zurich, Switzerland.

Abstract

BACKGROUND: Women with genetic susceptibility to breast cancer and indication for bilateral mastectomy are more likely to undergo implant-based breast reconstruction (IBR) than autologous breast reconstruction (ABR), while the impact of breast size in this context is insufficiently studied. Ultimately, comparative data on IBR and different types of ABR beyond abdominal-based flaps in genetic susceptible women remain scarce. This study aimed to evaluate factors associated with ABR and the effects of breast size for bilateral reconstruction in high-risk patients.
METHODS: A 2.5-year retrospective study was conducted at a single institution including all genetic high-risk patients who underwent bilateral mastectomy and breast reconstruction. Patients were stratified into two groups based on the weight of the mastectomy specimen. Small breast sizes were defined by mastectomy weights below 400 g, and medium-to-large breasts by specimen weights above 400 g. Binary logistic regression was performed to assess variables predictive of ABR, followed by an analysis of the breast size-dependent reconstructive algorithm and its complication rates.
RESULTS: We included 71 patients with BRCA1/2 (97.2%), CHEK2 (1.4%), and PALB2 (1.4%) mutations in the study. Among those, 68 IBRs and 74 ABRs were performed. Increasing age, immediate reconstruction, and medium-to-large breast size were predictive of ABR compared to IBR (p < 0.05). In the IBR-group, the majority of preoperative small breasts received subpectoral implant placements (81.0%, p = 0.003), while prepectoral implants (53.9%, p = 0.003) were preferred in medium-to-large breasts. In the ABR-group, the deep inferior epigastric artery (DIEP) flap was the choice in the vast majority of cases with larger breasts (86.4%, p < 0.001), whereas the transverse myocutaneous gracilis (TMG) flap (46.7%, p < 0.001) and superior gluteal artery perforator (SGAP) flap (20.0%, p = 0.002) were only considered in small-breasted patients. No elevated incidence of overall complications with increasing breast size was found. However, patients with larger breasts were more likely to undergo elective revisions after IBR (p < 0.001) as well as ABR (p = 0.013). With regard to two-stage tissue expander reconstructions, high-risk patients with larger breast size revealed increased explantations (p = 0.043) and expander-related revisions requiring additional surgery (p = 0.003). The latter was significantly reduced by reduction mammoplasty prior to expander placement (p = 0.036).
CONCLUSIONS: The preoperative breast size of gene mutation carriers influences the postmastectomy reconstructive choice. TMG and SGAP flaps are suitable options for bilateral reconstruction of genetic susceptible patients with small breasts, while DIEP flaps are preferred in larger breast sizes. With increasing breast size an elevated risk for elective revisions after either IBR or ABR need to be considered. Women with medium-to-large breasts exhibit increased morbidity related to expansion and genetic high-risk patients may benefit from prior reduction mammoplasty.

Keywords

References

  1. J Plast Reconstr Aesthet Surg. 2019 Oct;72(10):1623-1631 [PMID: 31445942]
  2. J Clin Med. 2021 Aug 17;10(16): [PMID: 34441926]
  3. Plast Reconstr Surg. 2016 Jul;138(1):29-40 [PMID: 27348637]
  4. Plast Reconstr Surg. 2024 Feb 1;153(2):281e-290e [PMID: 37159266]
  5. Ann Surg Oncol. 2013 Nov;20(12):3817-22 [PMID: 23740344]
  6. J Plast Reconstr Aesthet Surg. 2020 Mar;73(3):469-485 [PMID: 31987776]
  7. Breast Cancer Res Treat. 2020 Jul;182(2):421-428 [PMID: 32445176]
  8. Breast Cancer. 2020 May;27(3):435-444 [PMID: 31858435]
  9. Ann Plast Surg. 2013 May;70(5):506-12 [PMID: 23542837]
  10. Aesthetic Plast Surg. 2019 Oct;43(5):1173-1185 [PMID: 31367775]
  11. Gland Surg. 2019 Feb;8(1):43-52 [PMID: 30842927]
  12. Handchir Mikrochir Plast Chir. 2021 Apr;53(2):130-143 [PMID: 33860491]
  13. Aesthetic Plast Surg. 2022 Apr;46(2):706-711 [PMID: 34342702]
  14. Plast Reconstr Surg. 2020 Feb;145(2):303-311 [PMID: 31985608]
  15. Plast Reconstr Surg Glob Open. 2022 Apr 18;10(4):e4277 [PMID: 35450260]
  16. Int J Radiat Oncol Biol Phys. 2020 Mar 1;106(3):514-524 [PMID: 31756414]
  17. Breast J. 2017 Nov;23(6):706-712 [PMID: 28833889]
  18. Breast Cancer. 2020 Jan;27(1):70-76 [PMID: 31292927]
  19. Ann Plast Surg. 2016 Jun;76(6):640-4 [PMID: 25003439]
  20. Ann Oncol. 2015 Jul;26(7):1291-9 [PMID: 25605744]
  21. Plast Reconstr Surg. 2018 Jun;141(6):1341-1350 [PMID: 29794695]
  22. J Plast Reconstr Aesthet Surg. 2019 Sep;72(9):1518-1524 [PMID: 31196805]
  23. Int J Epidemiol. 2019 Jun 1;48(3):781-794 [PMID: 31243447]
  24. Plast Reconstr Surg. 2020 Apr;145(4):706e-714e [PMID: 32221200]
  25. Breast. 2014 Feb;23(1):38-43 [PMID: 24210736]
  26. Am J Surg. 2016 Oct;212(4):660-669 [PMID: 27649974]
  27. Plast Reconstr Surg. 2017 Aug;140(2):219-226 [PMID: 28746266]
  28. Plast Reconstr Surg Glob Open. 2014 Feb 07;2(1):e99 [PMID: 25289296]
  29. Breast Cancer Res Treat. 2018 Dec;172(3):523-537 [PMID: 30182349]
  30. Ann Plast Surg. 2022 May 1;88(3 Suppl 3):S205-S208 [PMID: 35513321]
  31. J Clin Oncol. 2023 Mar 20;41(9):1703-1713 [PMID: 36623243]
  32. Breast J. 2016 Jan-Feb;22(1):10-7 [PMID: 26782950]
  33. J Reconstr Microsurg. 2018 Jun;34(5):363-375 [PMID: 29510420]
  34. J Plast Reconstr Aesthet Surg. 2015 Jun;68(6):e129-30 [PMID: 25683679]
  35. Plast Reconstr Surg. 2019 Nov;144(5):1023-1032 [PMID: 31373992]
  36. J Am Coll Surg. 2020 Apr;230(4):535-541 [PMID: 32032724]
  37. BJS Open. 2018 Dec 19;3(2):135-145 [PMID: 30957059]
  38. Plast Reconstr Surg. 2017 Jan;139(1):30-39 [PMID: 28027223]
  39. Plast Reconstr Surg. 2018 Jun;141(6):795e-804e [PMID: 29794693]
  40. J Reconstr Microsurg. 2022 Sep;38(7):579-584 [PMID: 35135030]

MeSH Term

Humans
Female
Mammaplasty
Breast Neoplasms
Retrospective Studies
Middle Aged
Adult
Mastectomy
Breast
Mutation
Genetic Predisposition to Disease
Organ Size
BRCA2 Protein
BRCA1 Protein
Breast Implants

Chemicals

BRCA1 protein, human
BRCA2 protein, human
BRCA2 Protein
BRCA1 Protein

Word Cloud

Created with Highcharts 10.0.0breastreconstructionsizepatientsABRbreastsp = 0geneticmastectomyhigh-riskbilateralIBRmedium-to-largep < 0largercancerflapsstudy4%003flap001revisionsmutationcarriersWomenlikelyundergosusceptiblePatientsspecimensizesweights400 gperformedpredictivereconstructive1majoritypreoperativesmall0%preferredarteryDIEPchoiceTMGSGAPconsideredelevatedincreasingelectiveexpanderincreasedreductionmammoplastypriorEffectsBRCABACKGROUND:susceptibilityindicationimplant-basedautologousimpactcontextinsufficientlystudiedUltimatelycomparativedatadifferenttypesbeyondabdominal-basedwomenremainscarceaimedevaluatefactorsassociatedeffectsMETHODS:25-yearretrospectiveconductedsingleinstitutionincludingunderwentstratifiedtwogroupsbasedweightSmalldefinedBinarylogisticregressionassessvariablesfollowedanalysissize-dependentalgorithmcomplicationratesRESULTS:included71BRCA1/2972%CHEK2PALB2mutationsAmong68IBRs74ABRsIncreasingageimmediatecompared05IBR-groupreceivedsubpectoralimplantplacements81prepectoralimplants539%ABR-groupdeepinferiorepigastricvastcases86whereastransversemyocutaneousgracilis467%superiorglutealperforator20002small-breastedincidenceoverallcomplicationsfoundHoweverwell013regardtwo-stagetissuereconstructionsrevealedexplantations043expander-relatedrequiringadditionalsurgerylattersignificantlyreducedplacement036CONCLUSIONS:geneinfluencespostmastectomysuitableoptionsriskeitherneedexhibitmorbidityrelatedexpansionmaybenefitAutologousBilateralHereditaryImplant-basedRisk-reducing

Similar Articles

Cited By